Evidence map›Paper›PMID 42394714›Full record

ArticleJTO clinical and research reports2026

Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer.

Daniel Reinhorn, Jonathan Kuten, Isabel Preeshagul, Juliana Eng, Kenneth Ng, Alexander Drilon, Jamie Chaft, Fernando C Santini, Mark M Awad

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniel ReinhornDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Jonathan KutenDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York.
Isabel PreeshagulDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Juliana EngDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Kenneth NgDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Alexander DrilonDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Jamie ChaftDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Fernando C SantiniDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Mark M AwadDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background: Trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) are HER2-targeting antibody-drug conjugates (ADCs) with activity in Methods: We conducted a single-center retrospective study of patients with Results: Twenty-five patients were identified: 17 received T-DM1 post-T-DXd and 8 received T-DXd post-T-DM1. The median age for the entire cohort was 67 years; 56% were female. Most patients (21/25, 84%) harbored Conclusions: T-DXd retains clinical activity after prior T-DM1 use, whereas T-DM1 has limited efficacy after prior T-DXd in

Indexed as

Antibody-drug conjugateERBB2 mutationNon-small cell lung cancerTrastuzumab deruxtecanTrastuzumab emtansineTreatment sequencing

Identifiers

PMID42394714
PMCPMC13325295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.